The case for & against
Bull & Bear analysis
Bearish
DICE Therapeutics, formerly trading under the ticker symbol DICE, was a biotechnology company focused on developing oral therapeutics for chronic diseases. With an expertise in the discovery of small molecules, DICE was emerging in the biotherapeutics space. However, following its acquisition by Eli Lilly and Company in August 2023, DICE's common stock was delisted from the NASDAQ Global Market, rendering it no longer an independent entity on the stock exchange.
Bull says
- ↑August 2023 acquisition by Eli Lilly provides deep-pocketed R&D support
- ↑Lilly’s global distribution channels enable faster market entry for DICE therapies
- ↑Parent’s robust biopharma platform strengthens DICE’s therapeutic pipeline
- ↑Acquisition seen as validation of DICE’s small-molecule technology
- ↑Integration into Lilly ensures solid IP moat and capital commitment
Bear says
- ↓Post-August 2023 delisting eliminates standalone equity exposure
- ↓Integration may lead Lilly to discontinue non-core DICE projects
- ↓Strategic direction now driven by Lilly’s broader priorities
- ↓Investors lose liquidity and direct pipeline upside capture
- ↓DICE’s former growth drivers subsumed under parent company’s metrics